Outcome Differences between Intra-Arterial Iso- and Low-Osmolality Iodinated Radiographic Contrast Media in the Interventional Management of Stroke III Trial

Article Figures & Data

Table 1:

Baseline clinical characteristics considered for adjusted analysis

	Iodixanol	LOCM^{^a}	P Value
Age^{^b} (median) (range) (yr)	73 (47–83)	68.5 (24–82)	.07
Baseline glucose^{^b} (mmol/L) (median) (range)	6.9 (5.2–18.3)	6.6 (3.8–21.5)	.33
Diabetes (%)	19.4	17.7	.83
Baseline SBP (mm Hg)^{^b} (median) (range)	145.5 (116–185)	146 (102–194)	.82
History of high BP (%)	74.2	73.5	.94
Atrial fibrillation (%)	48.4	35.3	.19
Coronary artery disease (%)	35.5	19.6	.07
ASPECTS 8–10^{^b} (%)	41.9	49.0	.49
Baseline NIHSS^{^b}
≥20%	35.5	37.3	.86
≤19%	64.5	62.8
Historical mRS (No. Sx)^{^b} (%)	90.3	86.3	.46
Antiplatelet agents (%)	67.7	44.1	.02
Presumptive stroke location right (%)	51.6	49.0	.80
Baseline CTA/MRA (%)	61.3	51.0	.31

Note:—Sx indicates symptoms; SBP, systolic blood pressure; BP, blood pressure.
↵a Four LOCM (mOsm/Kg H₂O): iohexol (672), iopamidol (616), ioversol (651), iopromide (607).¹¹
↵b Baseline factors relevant to prespecified outcomes.

Table 2:

Relevant treatment-related variables considered for adjusted analysis

	Iodixanol	LOCM^{^a}	P Value
Time to IV therapy (min) (median)	124	115	.25
Onset to puncture (min) (median)	215	205	.29
Proximal M1 (vs distal) (%)	45.2	52.0	.51
Thrombolysis only (%)	41.9	36.2	.57
No. microcatheter injections (median)	1	2	.03
Heparin volume (U) (median)	3185	2986.8	.59
New emboli (%)	16.1	11.8	.54
IRCM volume (mL) (median)	85	64	.34
Infarct volume 24 hr (mL)^{^a} (median)	61.0	50.2	.23

↵a Four LOCM (mOsm/Kg H2O): iohexol (672), iopamidol (616), ioversol (651), iopromide (607).¹¹

Table 3:

Efficacy and safety outcomes according to iodixanol versus LOCM use

	Iodixanol (No.) (%)	LOCM (No.) (%)	Absolute % Risk Difference	Relative % Difference
N	31	102	–	–
mTICI 2b/3	16 (51.6)	42 (41.2)	10.4	20.2
mRS 0–2	11 (35.5)	31 (30.4)	5.1	14.4
AICH	9 (29.0)	42 (41.2)	−12.1	−29.6
SICH	2 (6.5)	9 (8.8)	−2.4	−26.1
Mortality	6 (19.4)	26 (25.5)	−6.1	−23.9

Table 4:

Relative risk of specified outcomes for iodixanol versus LOCM